Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Janux Therapeutics was founded in 2019 with the goal of revolutionizing the treatment of cancer and other diseases. We are focused on discovering, developing and commercializing novel therapies for the most challenging malignant and infectious diseases. We strive to create treatments that have a meaningful impact on patient outcomes and quality of life.
To transform the lives of patients by providing innovative and effective treatments for cancer and other diseases.
To be the leading biopharmaceutical company in the fight against cancer and other diseases.
Mr. Tommy Diraimondo Ph.D. (Sr. Director of Research)
Ms. Brenda Van Vreeswyk (Head of HR)
Mr. Andy Hollman Meyer (Chief Bus. Officer)
Mr. Byron Robinson J.D., Ph.D. (Chief Strategy Officer)
Mr. Charles M. Winter (Sr. VP of Chemistry, Manufacturing & Controls)
Recognition and Awards
Janux Therapeutics was recently named one of Forbes' Most Promising Startups of 2021.